



Oxford Conference on Innovation and Technology Transfer for Global Health

Bridging the Gap in Global Health Innovation – From Needs to Access

University of Oxford

9 -13 September 2007

***The conference was generously supported by
The Bill and Melinda Gates Foundation***

Conference Schedule¹

Monday, September 10

Plenary Lecture: Health Innovation: the neglected capacity of developing countries to address neglected diseases.

Dr. Carlos Morel, Scientific Director, Center for Technological Development in Health, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil

Dimensions of the challenges

Session Chair – John Kilama, Global Bioscience Development Institute

Free Market strategy in Healthcare: Key to achieving Product Availability and Access: Dr. Stephen Mallinga*², Minister of Health, Uganda

New Solutions for Global Health Challenges: Ms. Patricia Atkinson, Bill & Melinda Gates Foundation

Innovation, Access and Public Health: Dr. Harold Jaffe, University of Oxford

Who is listening to those in need?: Prof. Peter Ndumbe*, University of Buea

Challenges to vaccine financing and systems support: Rebecca Affolder, GAVI Alliance

The Intergovernmental Working Group: Dr. Howard Zucker, WHO

Strategies for Securing Product Availability and Access

Session Co-Chairs – Dr. Gill Samuels, Global Forum for Health Research, Ms. Dianna Derhak, DNA International Consultancy

¹ Please address any comments or queries to andrew.farlow@economics.ox.ac.uk.

² All speakers marked with an asterisk are Sanjaya Lall Fellows

Access to medicine: Pharma companies as part of the solution: Dr. Paul Herrling, Novartis and the Novartis Institute for Tropical Diseases (NITD)
The development of paromomycin IM for visceral leishmaniasis: Ms. Katherine Woo, Institute for One World Health

On the horizon developments in biotech and nanotechnology: Ms. Dianna Derhak, DNA International Consultancy

The Case of Merck: Dr. Diana Lanchoney, Merck

The Case of Ranbaxy and ARVs: Dr. Arun Purohit, Ranbaxy

The Case of Eli Lilly MDDR: Dr. Gail Cassell, Eli Lilly [Dr Gill Samuels]

The Case of Pfizer – Dr. Robert Mallett

Panel with discussion of all session papers

Tuesday, September 11

The Interface of Science, Technology Transfer and Access

Session Chair – Dr. Tony Bunn*, South Africa Medical Research Council

Biotechnology companies and Innovation: James Geraghty, Genzyme Corp.

Improving Access to Existing Global Health Solutions: Dr Devi Sridhar, Global Economic Governance Programme, University of Oxford

Designing of anti-counterfeiting solutions in a comprehensive patient centric healthcare system: Dr. P. Ganguli*, CEO, VISION-IPR, Mumbai

The Power of Networks for Innovation: Dr. Rafael Rangel-Aldao*, Simon Bolivar University

New Initiative in Japan: Prof. Katsuya Tamai, University of Tokyo

ICBG Program and its Impact in Academia, Conservation and Drug Discovery in Latin America: Prof. Barbara Timmermann, University of Kansas

Implementation of Biomedical and Information Technologies in Developing Countries: Prof. Eva Harris, Ministry of Health, Nicaragua and University of California

Panel with discussion of all session papers

Partnerships in Promoting Innovation and Managing Risk

Session Chair – Dr. K. Satyanarayana, Indian Council for Medical Research

Strategies for product innovation: the PDPs: Dr. Mary Moran, The George Institute

The Aeras Foundation: Achieving Access: Dr. Jerald Sadoff, Aeras Global TB Vaccine Foundation

Potential new approaches to scientific and financial innovation in PDPs - the example of AIDS vaccines: Mr. Labeeb M. Abboud, IAVI

PDVI – what is the end game?: Dr. Harold Margolis, PDVI

The PATH Strategy: Dr. Michael Free, PATH

The South African Malaria Initiative- a case study: Prof. Jane Morris*, African Centre for Gene Technologies

Wednesday, September 12

Partnerships in Promoting Innovation and Managing Risk (continued)

Session Chair – Mr. Andrew Farlow, University of Oxford

MMV - Moving to Access: Dr. Chris Hentschel, Medicines for Malaria Venture

IPM Case Study: Dr. Zeda Rosenberg, International Partnership for Microbicides (IPM)

The Evolution of PDPs: Best Practices: Prof Adrian Towse, Office of Health Economics

From recruitment to implementation of contemporary research in traditional environments:
Ms. Paulette Baukol, Mayo Clinic

Universities-Private Sector relationships in developing countries: Dr. Jose Miguel Flores*, Flores & Asociados, Universidad de Concepción

Desa Siaga - A Strategy for Health Investment: Siti Sundari*, Center for Health systems and Policy R&D, Indonesia

Managing Intellectual Property for Health and Agricultural Innovation

Session Chair - Prof. Linda Gonzales, University of Western Kentucky

The WTO TRIPS Agreement and Public Health: Ms. Jayashree Watal, World Trade Organization

TRIPS. Did the sky fall?: Prof. Keith Maskus, University of Colorado

IP and agricultural innovation: Prof. Magdy Madkour*, Egypt

IP, pharmaceuticals and foreign direct investment: Mr. Douglas Lippoldt, OECD

Case study: ICMR: Dr. K. Satyanarayana*, Indian Council for Medical Research

IP, Innovation and Access – New Insights from the MIHR/PIPRA Handbook: Dr. Anatole Krattiger, Arizona State University

Thursday, September 13

Financing for Innovation and Technology Transfer

Session Chair – Dr. Jose Miguel Flores, Flores & Asociados, Universidad de Concepción, Santiago, Chile

Who really pays? Three Donor Investment Choices: Prof Adrian Towse, Office of Health Economics

Axios Partnership in Tanzania: Dr. Anne Reeler*, Axios International

The Chile Foundation, Mr. Marcos Kulka*, Chile Foundation Case Study

The intersection of economics and access: Mr. Andrew Farlow, Saïd Business School,
University of Oxford

Funding for biotechnology in Africa: Prof. Diran Makinde*, NEPAD Biosciences, West
Africa Biosciences Network, Dakar, Senegal

Closing Wrap-up Session

Session Co-Chairs: Ms. Lita Nelsen, MIT and Dr. Peter Ndumbe*, University of Buea